News | January 06, 2026
PathoCare Holdings valued at $1.75 billion following major third-party tender offer
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Subscribe To Our Newsletter & Stay Updated
